Broad-Spectrum Candidates
Ebola/Marburg
Key Facts
About NanoViricides
NanoViricides is a clinical-stage biotech company developing a novel class of antiviral drugs called nanoviricides, designed to 'bind, engulf, and destroy' virus particles. Its core achievement is the development of a versatile, biomimetic nanomedicine platform with broad-spectrum potential against enveloped viruses, supported by a key strategic asset: a fully-owned, cGMP-capable manufacturing facility. The company's strategy leverages this platform to build a diverse pipeline targeting large markets like herpesviruses, respiratory viruses, and hemorrhagic fevers, with its most advanced program, NV-387 for MPox, having recently entered Phase II clinical trials.
View full company profileAbout NanoViricides
NanoViricides is a clinical-stage biotech company developing a novel class of antiviral drugs called nanoviricides, designed to 'bind, engulf, and destroy' virus particles. Its core achievement is the development of a versatile, biomimetic nanomedicine platform with broad-spectrum potential against enveloped viruses, supported by a key strategic asset: a fully-owned, cGMP-capable manufacturing facility. The company's strategy leverages this platform to build a diverse pipeline targeting large markets like herpesviruses, respiratory viruses, and hemorrhagic fevers, with its most advanced program, NV-387 for MPox, having recently entered Phase II clinical trials.
View full company profileAbout NanoViricides
NanoViricides is a clinical-stage biotech company developing a novel class of antiviral drugs called nanoviricides, designed to 'bind, engulf, and destroy' virus particles. Its core achievement is the development of a versatile, biomimetic nanomedicine platform with broad-spectrum potential against enveloped viruses, supported by a key strategic asset: a fully-owned, cGMP-capable manufacturing facility. The company's strategy leverages this platform to build a diverse pipeline targeting large markets like herpesviruses, respiratory viruses, and hemorrhagic fevers, with its most advanced program, NV-387 for MPox, having recently entered Phase II clinical trials.
View full company profileAbout NanoViricides
NanoViricides is a clinical-stage biotech company developing a novel class of antiviral drugs called nanoviricides, designed to 'bind, engulf, and destroy' virus particles. Its core achievement is the development of a versatile, biomimetic nanomedicine platform with broad-spectrum potential against enveloped viruses, supported by a key strategic asset: a fully-owned, cGMP-capable manufacturing facility. The company's strategy leverages this platform to build a diverse pipeline targeting large markets like herpesviruses, respiratory viruses, and hemorrhagic fevers, with its most advanced program, NV-387 for MPox, having recently entered Phase II clinical trials.
View full company profile